L-DOS47

· Helix BioPharma Corporation

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for L-DOS47, covering 2019-03-14 to 2025-05-06. Get the full timeline:

Most recent: Clinical Trial Update: L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer [Phase 1, Phase 2]